Skip to main content

Blog

Pfizer Discontinues Development of Investigational Mini-Dystrophin Gene Therapy

...

Response to the July 29th STAT Article

...

Making it Work: Practical Tips for Enhancing Quality of Life

...

ITF Therapeutics Announces U.S. Commercial Availability of DUVYZAT™ (givinostat) for Treatment of Duchenne

...

Navigating the Approved Therapy Landscape

...

PPMD’s 30th Annual Conference Session Recordings

...

PPMD Applauds FDA Launch of Rare Disease Innovation Hub — A Milestone for Rare Disease Patients

...

Capricor Therapeutics Announces Positive Skeletal Muscle and Cardiac Function Data from HOPE-2 OLE Study Data of Deramiocel (CAP-1002)

...

PPMD Convenes Leading Experts to Discuss Topics in Becker Care Ahead of 30th Annual Conference

...

REGENXBIO Announces Expansion of AFFINITY DUCHENNE® Trial to Include New Cohort of Younger Patients

...